Windlas Biotech Ltd approves Q2 FY27 results, with revenue of ₹263.91 crore and net profit of ₹18.05 crore
- Revenue rose 6.4% QoQ and 18.7% YoY; net profit increased 2.3% QoQ and 1.4% YoY. Calculated EBIT margin was 8.3%.
- Ashok Kumar Windlass resigned as whole-time director and director effective November 5; appointed Founder President and senior management personnel from November 6, subject to shareholder approval.
- Hitesh Windlass was appointed Chairman effective November 5. Auditors issued an unmodified limited-review conclusion.
